Kosei Taniguchi

Kosei Taniguchi

Auto-generated profile, based on publicly available information

Kosei Taniguchi

Department of Urology Kindai University Faculty of Medicine Osaka Japan

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2026 in IJU Case Reports
Verified
Journal Article
Open access
KTKosei Taniguchi
Kosei Taniguchi
MHMamoru Hashimoto
Mamoru Hashimoto
TNTakahito Nakayama
Takahito Nakayama
SFSaizo Fujimoto
Saizo Fujimoto
STShingo Toyoda
Shingo Toyoda
KFKazutoshi Fujita
Kazutoshi Fujita
Introduction: Upper tract urothelial carcinoma with neuroendocrine differentiation (UC‐NE) is extremely rare and generally associated with aggressive behavior and poor prognosis. Optimal treatment strategies remain unclear, particularly regarding the role of nectin‐4–targeted therapy. Case Presentation: A 61‐year‐old man was diagnosed with UC‐NE of the renal pelvis. Laparoscopic nephroureterectomy revealed invasive UC‐NE with lymphatic invasion (pT1, G2) and carcinoma in situ of the ureter (pTis, G1). Immunohistochemistry showed strong nectin‐4 expression in the urothelial component but only weak to moderate expression in the neuroendocrine component. Ten months after surgery, para‐aortic and bilateral pelvic lymph node recurrence developed. Treatment with enfortumab vedotin (EV) plus pembrolizumab achieved a complete response after 3 cycles, and remission was maintained with continued therapy. Conclusion: This case suggests that EV plus pembrolizumab may be effective for UC‐NE and highlights the importance of evaluating nectin‐4 and the tumor immune microenvironment when considering treatment strategies for this rare subtype.